Individual variability in both the capacity for thermogenesis [135,136] and intolerance to GLP-1–based therapies highlights the need for a personalized approach to obesity pharmacotherapy, emphasizing the importance of developing multiple therapeutic strategies that can be tailored to individual needs and extended to diverse populations, including children. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.